The device gained approval in the US in 2019 and received CE marking for use in the EU in 2014.

Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is ...

Elevated baseline LDH levels predict worse clinical outcomes in heart failure with reduced ejection fraction and modestly ...

Finerenone was associated with a 16% reduction for the primary composite endpoint of cardiovascular death and total HF events compared with placebo. The Food and Drug Administration (FDA) has accepted ...

Mayo model estimates heart function using a single echocardiographic image, enabling faster cardiac assessments in diverse clinical settings.

AHA scientific statement provides a framework for standardizing baseline and provocative invasive hemodynamic protocols in HF ...

Please provide your email address to receive an email when new articles are posted on . Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients ...

Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...